Insider selling always dwarfs buying, and this week it ran at $13.40 sold per dollar bought, right at the recent norm. The catch: the biggest ‘buys’ were a biotech financing round, an IPO-priced allocation taken by five insiders at one fixed price, and a controlling holder accumulating preferred, not fresh conviction.